Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
Morning Overview on MSN
A daraxonrasib trial just held pancreatic cancer in check for 8.5 months in most patients — twice as long as standard chemo for tumors that spread after first-line tr…
Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after ...
Most significant change years in pancreatic cancer drug demand drives Mayo Clinic and others to expand access and patient education on daraxonrasib.
The FDA's recent authorization of an expanded access program (EAP) for daraxonrasib (RMC-6236) has sparked widespread ...
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange ...
LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange ...
The US Food and Drug Administration's (FDA) expanded access program, sometimes referred to as its "Compassionate Use" program, has frequently been in the news as of late, as dozens of patients have ...
Please provide your email address to receive an email when new articles are posted on . The FDA authorized expanded access to daraxonrasib for patients with pretreated metastatic pancreatic cancer.
The U.S. Food and Drug Administration (FDA) has issued updated guidance on Expanded Access to Investigational Drugs for Treatment Use, clarifying how drug developers, physicians, and patients can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results